Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review

Rheumatology (Oxford). 2020 Apr 1;59(4):779-789. doi: 10.1093/rheumatology/kez300.

Abstract

Objectives: In severe rapidly progressive SSc, autologous haematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event-free survival. We undertook this study to identify, appraise and synthesize the evidence on health-related quality of life (HRQoL) before and after AHSCT for SSc.

Methods: We performed a systematic review of the literature, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed and ScienceDirect from database inception to 1 February 2019. All articles with original HRQoL data were selected.

Results: The search identified 1080 articles, of which 8 were selected: 3 unblinded randomized controlled trials [American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST), Autologous Stem Cell Transplantation International Scleroderma, Scleroderma: Cyclophosphamide or Transplantation), 3 uncontrolled phase I or II trials and 2 cohort studies. HRQoL data from 289 SSc patients treated with AHSCT and 125 treated with intravenous CYC as a comparator with median 1.25-4.5 years follow-up were included. HRQoL was evaluated with the HAQ Disability Index (HAQ-DI; 275 patients), the 36-item Short Form Health Survey (SF-36; 249 patients) and the European Quality of Life 5-Dimensions questionnaire (EQ-5D; 138 patients). The quality of the studies was moderate to low. AHSCT was associated with significant improvement in the HAQ-DI (P = 0.02-<0.001), SF-36 Physical Component Summary score (P = 0.02-<0.0001) and EQ-5D index-based utility score (P < 0.001). The SF-36 Mental Component Summary score improved in the ASSIST (n = 19) and one small retrospective cohort (n = 30 patients, P = 0.005) but did not improve significantly in 2 randomized controlled trials (n = 200 patients, P = 0.1-0.91).

Conclusion: AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL.

Keywords: autologous haematopoietic stem cell transplantation; quality of life; systemic sclerosis.

Publication types

  • Systematic Review

MeSH terms

  • Antirheumatic Agents / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Quality of Life*
  • Scleroderma, Systemic / physiopathology
  • Scleroderma, Systemic / psychology
  • Scleroderma, Systemic / therapy*
  • Severity of Illness Index
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Cyclophosphamide